List details
Basic info
| Status |
Withdrawn
|
| Details on the scope of restriction |
A derogation for the import and use in pharmaceutical products for the treatment of pulmonary diseases in entry 68 of Annex XVII: Perfluorooctanoic acid (PFOA), its salts and related substances.
|
| Reason for restriction |
This use was not identified during the processing of the PFOA restriction, and the Commission requested ECHA to review the derogation request of AstraZeneca.
|
Intention timeline
| Date of intention |
2018-05-16
|
| Expected date of submission |
2018-06-20
|
| Withdrawal date |
2020-10-14
|
| Latest update |
2020-10-16
|
Support information
| Reason for withdrawal |
After preparation, this report was processed for an opinion from RAC and SEAC via the procedure outlined in REACH Article 77(3)(c). Please refer to the dedicated Article 77(3)(c) pages on the ECHA website for details and related documents: RAC https://echa.europa.eu/about-us/who-we-are/committee-for-risk-assessment/opinions-of-the-rac-adopted-under-specific-echa-s-executive-director-requests SEAC https://echa.europa.eu/opinions-of-the-seac-adopted-under-specific-echa-s-executive-director-requests
|
| Restriction report and annexes |
|
Related substances
By adding any of the following substances to your watchlist, you would be monitoring this regulatory record and all possible new regulatory records related to that substance.
-
1-[[3-(dimethylamino)propyl]amino]-4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,13-henicosafluorotridecan-2-ol
CAS: 94159-80-5, EC: 303-261-1
Related regulatory records
Add the related substance to your watchlist to monitor this regulatory record.